期刊文献+

CIK细胞对晚期非小细胞肺癌预后的影响 被引量:8

The Prognostic Analysis of the Therapeutics of Cytokine induced Killer Cells on the Patients with Advanced Non Small Cell Lung Cancer
暂未订购
导出
摘要 目的观察细胞因子诱导的杀伤细胞(CIK细胞)体外培养后,对晚期非小细胞肺癌的疗效。方法收集经确诊的、并发生转移、且采用标准治疗方案的非小细胞肺癌患者20例作为观察组,取外周血分离单个核细胞(PBMC),体外细胞因子诱导培养CIK细胞,流式细胞仪检测细胞表型。20例患者均接受CIK细胞免疫治疗,观察其免疫活性及生存期。并以20例采用标准治疗方案而未经CIK治疗的晚期非小细胞肺癌患者作为对照组。结果观察组培养后的细胞表型CD3、CD3+CD56+明显升高,生存期为(16.15±3.8)个月,对照组生存期为(9.12±3.2)个月。结论经CIK细胞治疗后晚期非小细胞肺癌患者的生存期明显延长。 Objective It is to investigate the cytotoxicity in vitro of cytokine-induced killer(CIK) cells after coculturing,and to observe their clinical antitumour efficacy,immunological activity.Methods Peripheral blood mononuclear cells(PBMC) were isolated from 20 patients with advanced non small cell lung cancer,who had been treated with standard protocol.CIK cells were induced and coculture in vitro.The phenotypes changes of CIK cells were identified by flow cytometric analysis.20 patients were treated with CIK cells for immunotherapy,and we evaluated their clinical antitumour efficacy,immunological activity and survival instances of them.Results The survival of the experiment group was(16.15±3.8)months,while the other group was(9.12±3.2)months,which was statistically significantly different(P 0.05).Conclusion CIK is effective to advanced non small cell lung cancer and it can imp rove the prognosis of them.
出处 《实用癌症杂志》 2011年第6期573-574,共2页 The Practical Journal of Cancer
关键词 细胞因子诱导的杀伤细胞 非小细胞肺癌 免疫治疗 Cytokine-induced killer cells Non small cell lung cancer Immunotherapy
  • 相关文献

参考文献2

二级参考文献36

  • 1Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M,Dorbic T, Neubauer A, Wittig B, Huhn D. Phase Ⅰ clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999, 81:1009-1016.
  • 2Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001, 7:216-222.
  • 3Marten A, Ziske C, Schottker B, Renoth S, Weineck S,Buttgereit P, Schakowski F, von Rucker A, Sauerbruch T,Schmidt-Wolf IG. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 2001, 24:502-510.
  • 4Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins.Blood 1993, 81:1607-1613.
  • 5Gold JE, Zachary DT, Osband ME. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. Int J Cancer 1995, 61:580-586.
  • 6Schmidt-Wolf IG, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta BA, Tsuruo T, Huhn D, Negrin RS. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 1996, 169:85-90.
  • 7Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X,Ye DX. Molecular cloning and characterization of LAPTM4B,a novel gene upregulated in hepatocellular carcinoma.Oncogene 2003, 22:5060-5069.
  • 8Zhang YS, Dai ZQ. Advances in Hepatoma Biotherapy Research. Zhongguo Xiandai Putong Waike Jinzhan 2001, 4:193-198.
  • 9Kline NE. Promoting patient safety through the development of a pediatric chemotherapy and biotherapy provider program. J Pediatr Oncol Nurs 2004, 21:65-66.
  • 10Tan GH, Wei YQ, Tian L, Zhao X, Yang L, Li J, He QM, Wu Y,Wen YJ, Yi T, Ding ZY, Kan B, Mao YQ, Deng HX, Li HL,Zhou CH, Fu CH, Xiao F, Zhang XW. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol 2004, 34: 2012-2021.

共引文献48

同被引文献44

  • 1尹立杰,赵国华,丁田贵,彭兆祥,侯秀芬.金龙胶囊联合全身伽玛刀治疗晚期胰腺癌临床观察[J].中国肿瘤临床,2004,31(19):1129-1131. 被引量:11
  • 2林丽珠,陶志广,周岱翰.WHO标准和RECIST在肺癌多中心疗效评价的比较[J].中国肿瘤临床,2006,33(5):253-255. 被引量:42
  • 3吴擘颋,徐建民.CIK细胞:过去、现在与将来[J].中国临床医学,2006,13(5):782-784. 被引量:15
  • 4李成海,鲁心安,高锋,胡雷光.用流式细胞仪监测放疗肿瘤患者淋巴细胞亚群[J].中华放射医学与防护杂志,2007,27(3):255-256. 被引量:10
  • 5Chang GC, Tsai CM, Chert KC, et al. Predictive factors of gefitinib antitumor activity in east Asian advanced non-small cell lung cancer patients[J]. J Thorac Oncol, 2006, 1(6):520-525.
  • 6李建生.金龙胶囊的研究与开发[J].中国肿瘤临床与康复,1998,5:2-5.
  • 7Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer:a randomized trial[J]. J Clin Oncol, 1997, 15(6):2403-2413.
  • 8中华人民共和国卫生部.原发性肺癌诊疗规范(2011年版)[EB/OL]http://www.moh.gov.cn/publicf_les/business/htmlfiles/mohyzs/s3586/201102/50756.html,2011-02-25.
  • 9Shrestha S,Joshi P. Gefitinib monotherapy in advanced non-small-cell lung cancer:a retrospective analysis. JNMA J Nepal MedAssoc,2012,52(186):66-71.
  • 10Morisaki T,Onishi H,Koya N,et al. Combinatorial cytotoxicity ofgemcitabine and cytokine-activated killer cells in hepatocellularcarcinoma via the NKG2D-MICA/B system. Anticancer Res,2011,31(7):2505-2510.

引证文献8

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部